GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AIM ImmunoTech Inc (AMEX:AIM) » Definitions » Equity-to-Asset
中文

AIM ImmunoTech (AIM ImmunoTech) Equity-to-Asset : 0.53 (As of Dec. 2023)


View and export this data going back to 1995. Start your Free Trial

What is AIM ImmunoTech Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. AIM ImmunoTech's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $10.23 Mil. AIM ImmunoTech's Total Assets for the quarter that ended in Dec. 2023 was $19.38 Mil. Therefore, AIM ImmunoTech's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was 0.53.

The historical rank and industry rank for AIM ImmunoTech's Equity-to-Asset or its related term are showing as below:

AIM' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.37   Med: 0.84   Max: 0.99
Current: 0.53

During the past 13 years, the highest Equity to Asset Ratio of AIM ImmunoTech was 0.99. The lowest was 0.37. And the median was 0.84.

AIM's Equity-to-Asset is ranked worse than
61.76% of 1564 companies
in the Biotechnology industry
Industry Median: 0.66 vs AIM: 0.53

AIM ImmunoTech Equity-to-Asset Historical Data

The historical data trend for AIM ImmunoTech's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AIM ImmunoTech Equity-to-Asset Chart

AIM ImmunoTech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.65 0.95 0.99 0.95 0.53

AIM ImmunoTech Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.95 0.93 0.90 0.81 0.53

Competitive Comparison of AIM ImmunoTech's Equity-to-Asset

For the Biotechnology subindustry, AIM ImmunoTech's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AIM ImmunoTech's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AIM ImmunoTech's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where AIM ImmunoTech's Equity-to-Asset falls into.



AIM ImmunoTech Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

AIM ImmunoTech's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=10.234/19.381
=0.53

AIM ImmunoTech's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )=Total Stockholders Equity/Total Assets
=10.234/19.381
=0.53

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


AIM ImmunoTech  (AMEX:AIM) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


AIM ImmunoTech Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of AIM ImmunoTech's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


AIM ImmunoTech (AIM ImmunoTech) Business Description

Traded in Other Exchanges
Address
2117 SW Highway 484, Ocala, FL, USA, 34473
AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders, viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases and drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer and triple negative metastatic breast cancer. The company is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.
Executives
Thomas K. Equels director, officer: Vice Chairman of Board 2117 SOUTHWEST HIGHWAY 484, OCALA FL 34473
Nancy Bryan director 550 HILLS DRIVE, 3RD FLOOR, BEDMINSTER NJ 07921
Stewart Appelrouth director 2117 SW HIGHWAY 484, OCALA FL 34473
Rodino Peter W. Iii director 2117 SOUTHWEST HIGHWAY 484, OCALA FL 34473
Ellen M Lintal officer: CFO 2117 SW HWY 484, OCALA FL 34473
William M Mitchell director 2117 SW HWY 484, OCALA FL 34473
Wayne S. Springate officer: VP of Operations 600 MAIN STREET, SUITE 2, RIVERTON NJ 08077
David R Strayer other: Medical Director 600 MAIN STREET, SUITE 2, RIVERTON NJ 08077
Adam Pascale officer: CFO 600 MAIN STREET, SUITE 2, RIVERTON NJ 08077
Ralph Christopher Cavalli officer: VP, Quality Control 510 MURDOCH ROAD, PHILADELPHIA PA 19119
Russel J Lander officer: VP of Process/QualityAssurance 784 BAEDER ROAD, JENKINTOWN PA 19046
Robert Iv Dickey officer: Senior Vice President 320 WEST MERMAID LANE, PHILADELPHIA PA 19118
Bernhardt Charles Thomas Iii officer: CFO 23 BIRCH ROAD, MALVERN PA 19355
Steven D Spence director 250 EAST 54TH STREET APARTMENT 36C, NEW YORK NY 10022
Anthony Bonelli officer: President & COO P.O. BOX 521, NEW VERNON NJ 07976

AIM ImmunoTech (AIM ImmunoTech) Headlines

From GuruFocus

Could Insider Buying Signal that AIM ImmunoTech Inc Is Undervalued?

By GuruFocus Research GuruFocus Editor 01-04-2023